These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38921803)

  • 41. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.
    Kanai D; Wakui H; Hanaoka M; Haze T; Azushima K; Shinoda S; Tsukamoto S; Taguchi S; Kinguchi S; Kanaoka T; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
    Clin Exp Nephrol; 2023 Jul; 27(7):639-647. PubMed ID: 36977892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination.
    Almendro-Vázquez P; Laguna-Goya R; Ruiz-Ruigomez M; Utrero-Rico A; Lalueza A; Maestro de la Calle G; Delgado P; Perez-Ordoño L; Muro E; Vila J; Zamarron I; Moreno-Batanero M; Chivite-Lacaba M; Gil-Etayo FJ; Martín-Higuera C; Meléndez-Carmona MÁ; Lumbreras C; Arellano I; Alarcon B; Allende LM; Aguado JM; Paz-Artal E
    PLoS Pathog; 2021 Dec; 17(12):e1010211. PubMed ID: 34962970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination.
    Montmaneix-Engels F; Dimeglio C; Staes L; Da Silva I; Porcheron M; Jougla I; Hérin F; Izopet J
    Heliyon; 2024 Apr; 10(7):e29116. PubMed ID: 38601689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.
    Mangia A; Serra N; Cocomazzi G; Giambra V; Antinucci S; Maiorana A; Giuliani F; Montomoli E; Cantaloni P; Manenti A; Piazzolla V
    Front Public Health; 2022; 10():847384. PubMed ID: 35433614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.
    Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
    Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
    Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
    Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
    Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
    Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
    Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
    Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
    Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
    Koehm M; Klippstein M; Dauth S; Hallmann K; Kohmer N; Burkhardt H; Ciesek S; Geisslinger G; Rabenau HF; Behrens F
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.
    Gómez de la Torre JC; Hueda-Zavaleta M; Cáceres-DelAguila JA; Muro-Rojo C; Cruz-Escurra N; Benítes-Zapata VA
    Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37242998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.